EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, HALO:

28 Aug 2025
LAST:

72.81

CHANGE:
 0.37		OPEN:
72.85		HIGH:
72.88		ASK:
11.45		VOLUME:
1.48M
CHG(%):
0.51		PREV:
73.18		LOW:
72.07		BID:
8.75		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Aug 2572.8572.8872.0772.811.48M
27 Aug 2572.9374.0772.9373.183.21M
26 Aug 2572.4372.9771.9172.932.28M
25 Aug 2572.0073.4772.0072.211.64M
22 Aug 2571.6272.0970.3271.822.44M
21 Aug 2571.1372.3370.5571.611.86M
20 Aug 2569.7071.2169.5371.131.89M
19 Aug 2569.0670.7068.9969.983M
18 Aug 2568.1969.0567.9568.961.85M
15 Aug 2566.1567.4065.7767.271.67M

COMPANY PROFILE

Name:
About:Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:12390 El Camino Real, San Diego, CA, United States, 92130
Website:https://halozyme.com
CUSIP:40637H109
CIK:0001159036
ISIN:US40637H1095
FIGI:BBG000CZ8W54
LEI:529900242I3SV9AGM753

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:16.01
PtB:24.24
PtS:6.94
EBITDA:758.6M
Shares:116.97M
Market Cap:8.516B

TECHNICAL INDICATORS

MA5:72.59
MA10:71.19
MA20:66.83
MA50:60.26
MA100:58.63
MA200:56.79
STO9:75.34
STO14:88.73
RSI14:96.44
WPR14:-3.60
MTM14:9.92
ROC14:0.16
ATR:1.53
Week High:74.07
Week Low:70.32
Month High:74.07
Month Low:57.68
Year High:74.07
Year Low:42.01
Volatility:7.89